Ghahramani P - Search Results

1

Relationship Between Plasma Concentrations and Clinical Effects of Cariprazine in Patients With Schizophrenia or Bipolar Mania.

Periclou A, Willavize S, Jaworowicz D, Passarell J, Carrothers T, Ghahramani P, Durgam S, Earley W, Kapás M, Khariton T. Periclou A, et al. Among authors: ghahramani p. Clin Transl Sci. 2020 Mar;13(2):362-371. doi: 10.1111/cts.12720. Epub 2019 Dec 27. Clin Transl Sci. 2020. PMID: 31664765 Free PMC article.

2

Population Pharmacokinetics of Cariprazine and its Major Metabolites.

Periclou A, Phillips L, Ghahramani P, Kapás M, Carrothers T, Khariton T. Periclou A, et al. Among authors: ghahramani p. Eur J Drug Metab Pharmacokinet. 2021 Jan;46(1):53-69. doi: 10.1007/s13318-020-00650-4. Eur J Drug Metab Pharmacokinet. 2021. PMID: 33141308 Free PMC article.

3

Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO.

Girgis RR, Slifstein M, D'Souza D, Lee Y, Periclou A, Ghahramani P, Laszlovszky I, Durgam S, Adham N, Nabulsi N, Huang Y, Carson RE, Kiss B, Kapás M, Abi-Dargham A, Rakhit A. Girgis RR, et al. Among authors: ghahramani p. Psychopharmacology (Berl). 2016 Oct;233(19-20):3503-12. doi: 10.1007/s00213-016-4382-y. Epub 2016 Aug 15. Psychopharmacology (Berl). 2016. PMID: 27525990 Free PMC article.

4

Levomilnacipran Pharmacokinetics in Healthy Volunteers Versus Patients with Major Depressive Disorder and Implications for Norepinephrine and Serotonin Reuptake Inhibition.

Chen L, Greenberg WM, Gommoll C, O'Connor J, Zukin SR, Periclou A, Ghahramani P. Chen L, et al. Among authors: ghahramani p. Clin Ther. 2015 Sep;37(9):2059-70. doi: 10.1016/j.clinthera.2015.07.005. Epub 2015 Aug 20. Clin Ther. 2015. PMID: 26256429 Clinical Trial.

5

Effect of hepatic impairment on the pharmacokinetics of levomilnacipran following a single oral dose of a levomilnacipran extended-release capsule in human participants.

Chen L, Boinpally R, Greenberg WM, Wangsa J, Periclou A, Ghahramani P. Chen L, et al. Among authors: ghahramani p. Clin Drug Investig. 2014 May;34(5):351-9. doi: 10.1007/s40261-014-0182-5. Clin Drug Investig. 2014. PMID: 24677141 Clinical Trial.

6

Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans.

Chen L, Greenberg WM, Brand-Schieber E, Wangsa J, Periclou A, Ghahramani P. Chen L, et al. Among authors: ghahramani p. Drug Des Devel Ther. 2015 Jun 25;9:3293-300. doi: 10.2147/DDDT.S85418. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26150701 Free PMC article. Clinical Trial.

7

Evaluation of Cytochrome P450 (CYP) 3A4-Based Interactions of Levomilnacipran with Ketoconazole, Carbamazepine or Alprazolam in Healthy Subjects.

Chen L, Boinpally R, Gad N, Greenberg WM, Wangsa J, Periclou A, Ghahramani P. Chen L, et al. Among authors: ghahramani p. Clin Drug Investig. 2015 Oct;35(10):601-12. doi: 10.1007/s40261-015-0318-2. Clin Drug Investig. 2015. PMID: 26315684 Clinical Trial.

8

A Single-Center, Open-Label, 3-Way Crossover Trial to Determine the Pharmacokinetic and Pharmacodynamic Interaction Between Nebivolol and Valsartan in Healthy Volunteers at Steady State.

Chen CL, Desai-Krieger D, Ortiz S, Kerolous M, Wright HM, Ghahramani P. Chen CL, et al. Among authors: ghahramani p. Am J Ther. 2015 Sep-Oct;22(5):e130-40. doi: 10.1097/MJT.0000000000000247. Am J Ther. 2015. PMID: 25853236 Free PMC article. Clinical Trial.

9

A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of a First-in-Human Engineered Cationic Peptide, PLG0206, Intravenously Administered in Healthy Subjects.

Huang D, Dobbins D, Ghahramani P, Friedland I, Steckbeck J. Huang D, et al. Among authors: ghahramani p. Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0144121. doi: 10.1128/AAC.01441-21. Epub 2021 Nov 22. Antimicrob Agents Chemother. 2022. PMID: 34807760 Free PMC article. Clinical Trial.

10

Engineered peptide PLG0206 overcomes limitations of a challenging antimicrobial drug class.

Huang DB, Brothers KM, Mandell JB, Taguchi M, Alexander PG, Parker DM, Shinabarger D, Pillar C, Morrissey I, Hawser S, Ghahramani P, Dobbins D, Pachuda N, Montelaro R, Steckbeck JD, Urish KL. Huang DB, et al. Among authors: ghahramani p. PLoS One. 2022 Sep 16;17(9):e0274815. doi: 10.1371/journal.pone.0274815. eCollection 2022. PLoS One. 2022. PMID: 36112657 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

35 results

Search Page

Filters